Can a new drug outsmart resistant breast cancer?
Disease control
Not yet recruiting
This phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink t…
Phase: PHASE2 • Sponsor: Chengdu SciMount Pharmatech Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC